Arecor Therapeutics PLC ( (GB:AREC) ) has provided an update.
Arecor Therapeutics has entered into an exclusive licensing agreement for AT351, a ready-to-dilute liquid formulation of a critical care therapy, with a major chemicals marketing company’s subsidiary. This agreement allows the licensee to further develop and commercialize AT351, which could significantly simplify care and reduce costs in the supply chain. Arecor will receive milestone payments and royalties, enhancing its market position and validating its technology strategy.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a biopharmaceutical company that focuses on transforming patient care through innovative medicines by enhancing existing therapeutic products. The company employs its proprietary technology platform, Arestat™, to develop a portfolio of products in areas such as diabetes, while collaborating with pharmaceutical and biotechnology companies to advance therapeutic solutions.
YTD Price Performance: -61.92%
Average Trading Volume: 10,359
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £26.24M
See more insights into AREC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com